Efficacy and safety of PF-00299804 (PF299). an oral, irreversible, part-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC)

被引：17
|
作者：
Mok, T.
Spigel, D. R.
Park, K.
Socinski, M. A.
Tung, S. Y.
Kim, D.
Borzillo, G.
Zhang, H.
O'Connell, J. P.
Janne, P. A.
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[2] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[3] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[6] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[7] Pfizer Inc, New London, CT USA
[8] Pfizer Res & Dev Co Ltd, Shanghai, Peoples R China
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7537
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
    Toshiaki Takahashi
    Narikazu Boku
    Haruyasu Murakami
    Tateaki Naito
    Asuka Tsuya
    Yukiko Nakamura
    Akira Ono
    Nozomu Machida
    Kentaro Yamazaki
    Junichiro Watanabe
    Ana Ruiz-Garcia
    Keiji Imai
    Emiko Ohki
    Nobuyuki Yamamoto
    Investigational New Drugs, 2012, 30 : 2352 - 2363
  • [22] The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
    Feng, Yongdong
    Zhu, Guangkuo
    Lang, Song
    Hao, Ping
    Li, Guanghui
    Chen, Fanglin
    Zhuo, Wenlei
    Duan, Yuzhong
    Zhang, Anmei
    Chen, Zhengtang
    Sun, Jianguo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] GASTROINTESTINAL TOXICITY OF THE PAN-HER TYROSINE KINASE INHIBITOR (TKI) PF299804: ASSESSMENT BY PATIENT-REPORTED OUTCOMES IN 2ND/3RD-LINE AND REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
    Campbell, Alicyn K.
    Blackhal, Fiona H.
    Gadgeel, Shirish M.
    Janne, Pasi A.
    Park, Keunchil
    Mundayat, Rajiv
    Letrent, Stephen P.
    Boyer, Michael
    O'Connell, Joseph
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1184 - S1185
  • [24] Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
    Takeyasu, Y.
    Goto, Y.
    Morita, R.
    Sato, J.
    Murakami, S.
    Horinouchi, H.
    Fujiwara, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Lopes, G.
    Segel, J.
    Tan, D. S. W.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Efficacy, Safety And Dosage Of Afatinib In Patients With Non-Small Cell Lung Cancer After Failure Of Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-Tki)
    Park, C.
    Kim, T.
    Shin, H.
    Ban, H.
    Lim, J.
    Kwon, Y.
    Oh, I.
    Kim, Y.
    Lim, S.
    Kim, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [27] DERMATOLOGIC ADVERSE EVENTS OF THE PAN-HER TYROSINE KINASE INHIBITOR (TKI) PF299804: ASSESSMENT BY PATIENT-REPORTED OUTCOMES IN 2ND/3RD-LINE AND REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
    Campbell, Alicyn K.
    Boyer, Michael
    Giaccone, Giuseppe
    Janne, Pasi A.
    Kim, Dong-Wan
    Park, Keunchil
    Ramalingam, Suresh
    Reckamp, Karen L.
    Mundayat, Rajiv
    Letrent, Stephen P.
    O'Connell, Joseph
    Lacouture, Mario E.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1185 - S1186
  • [28] Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer
    Okauchi, Shinichiro
    Miyazaki, Kunihiko
    Satoh, Hiroaki
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (02): : 123 - 127
  • [29] A review of pharmacological costs of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Clinical Significance of Sequential Treatment with Afatinib in the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Treatment of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kobayashi, N.
    Aiko, H.
    Kamimaki, C.
    Mikami, N.
    Kubo, S.
    Tei, Y.
    Hirama, N.
    Katakura, S.
    Teranishi, S.
    Manabe, S.
    Yamamoto, M.
    Kudo, M.
    Kaneko, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345